12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ibrutinib: Phase II data

An open-label, U.S. Phase II trial in 13 MM patients with progressive disease after >=2 prior lines of therapy showed that once-daily 420 mg oral ibrutinib produced no partial or complete responses. Pharmacyclics said that several patients achieved stable disease and minor response. The company has expanded the trial, which is...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >